Real‑world effectiveness of venetoclax‑rituximab in relapsed or refractory chronic lymphocytic leukemia in Belgium: results from the AREVEDECY study
Annals of Hematology · 21.11.2026
DOI: 10.1007/s00277-026-07356-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 21.11.2026. Verfasst von Sylvia Snauwaert und 10 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Outcomes from the Phase 3 MURANO trial support the efficacy of a two‑year regimen of venetoclax + rituximab (VenR) in relapsed/refractory chronic lymphocytic leukemia (R/R CLL). To evaluate outcomes with the Belgian reimbursed VenR treatment strategy in routine clinical practice, we conducted a retrospective chart review of adults with R/R CLL prescribed VenR at nine clinical centers in Belgium. Data were collected from September 2019 until site‑specific ethical approval (October 2022–February 2023). 117 patients were included in the VenR-intended cohort, with records observed for a mean 19.2 (standard deviation, 10.5) months. At index, mean age was 71 years; 45% of patients had prior Bruton tyrosine kinase inhibitor (BTKi) exposure. Overall response rate was 90% among patients with an available response assessment. At 24 months, estimated overall survival (OS) was 80.8% (95% confidence interval [CI], 72.8%–89.6%), progression-free survival (PFS) was 77.5% (95% CI, 69.1%–87.0%). 82 patients (70%) received ≥ 1 rituximab administration; 35 (30%) did not, most commonly (71%) due to COVID-19-related circumstances; 24-month OS and PFS were lower in patients not receiving rituximab (OS: 69.3% vs. 85.7%; PFS: 69.6% vs. 80.8%). BTKi-experienced patients had numerically lower 24-month OS (75.5% vs. 84.7%) and PFS (70.0% vs. 83.2%) than BTKi-naïve patients. Treatment discontinuations occurred in 39% of patients, and dose reductions in 29%. Mean daily venetoclax dose was 328.5 mg. Overall, real-world outcomes with the Belgian reimbursed VenR treatment strategy were broadly consistent with MURANO trial outcomes, despite substantial proportions of this sample having BTKi experience or never receiving rituximab.
Förderung
- AbbVie
Zitieren
APA
Snauwaert, S., Meers, S., Maertens, V., Poedts, L., Ghys, L., Bevere, M. D., Gillon, B., Vandeweerd, L., Lettens, T., Morrens, J., & Janssens, A. (2026). Real‑world effectiveness of venetoclax‑rituximab in relapsed or refractory chronic lymphocytic leukemia in Belgium: results from the AREVEDECY study. Annals of Hematology. https://doi.org/10.1007/s00277-026-07356-8
Vancouver
Snauwaert S, Meers S, Maertens V, Poedts L, Ghys L, Bevere MD, et al. Real‑world effectiveness of venetoclax‑rituximab in relapsed or refractory chronic lymphocytic leukemia in Belgium: results from the AREVEDECY study. Annals of Hematology. 2026. doi:10.1007/s00277-026-07356-8
BibTeX
@article{Snauwaert2026,
author = {Snauwaert, Sylvia and Meers, Stef and Maertens, Vincent and Poedts, Laurens and Ghys, Liesbeth and Bevere, Michel De and Gillon, Barbara and Vandeweerd, Laura and Lettens, Thomas and Morrens, Joachim and Janssens, Ann},
title = {Real‑world effectiveness of venetoclax‑rituximab in relapsed or refractory chronic lymphocytic leukemia in Belgium: results from the AREVEDECY study},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-07356-8}
}
EUVIMED